Brexit Effects On Medtech: View From Switzerland
Executive Summary
While medtech trading economies and major exporting firms agonize over the effects that Brexit will have on their own future prospects, Switzerland, small in geographic terms but a major player in medtech and the global health care products industries generally, has been among the first to quantify its concerns.
You may also be interested in...
Brexit Effect On UK Medtech: View From The US
A few short weeks after the UK public voted in favor of leaving the EU – and several high-profile political casualties later – the issue is not yet of the Brexit dust settling, but of nervous preparations for when it will. Economic commentators, weighed down by news overkill, say that the true indications of what lies ahead are at least another month away: bad news indeed for those who find the short-term ride plenty bumpy enough.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.